Sutro Biopharma (NASDAQ:STRO) Rating Increased to Buy at HC Wainwright

HC Wainwright upgraded shares of Sutro Biopharma (NASDAQ:STRO) from a neutral rating to a buy rating in a report issued on Tuesday morning, MarketBeat.com reports. The brokerage currently has $28.00 target price on the stock, up from their previous target price of $10.00.

A number of other research firms have also recently issued reports on STRO. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th. Citigroup raised Sutro Biopharma to an “outperform” rating in a report on Tuesday, January 20th. Citizens Jmp upgraded Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price for the company in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. Finally, Wedbush reissued a “neutral” rating and set a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Sutro Biopharma currently has a consensus rating of “Hold” and an average target price of $34.33.

Sutro Biopharma Stock Performance

NASDAQ STRO opened at $23.57 on Tuesday. Sutro Biopharma has a 52-week low of $5.23 and a 52-week high of $26.54. The company has a fifty day moving average of $18.39 and a 200-day moving average of $12.68. The company has a market capitalization of $200.58 million, a P/E ratio of -0.90 and a beta of 1.47.

Sutro Biopharma (NASDAQ:STRO) last released its earnings results on Monday, March 23rd. The company reported ($5.39) EPS for the quarter, missing analysts’ consensus estimates of ($4.66) by ($0.73). Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. The firm had revenue of $11.65 million during the quarter, compared to the consensus estimate of $9.26 million. As a group, analysts forecast that Sutro Biopharma will post -2.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Sutro Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in STRO. Invesco Ltd. boosted its holdings in Sutro Biopharma by 137.8% in the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after acquiring an additional 53,390 shares in the last quarter. AQR Capital Management LLC increased its position in Sutro Biopharma by 1,052.8% during the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock valued at $859,000 after purchasing an additional 1,206,330 shares during the period. Strs Ohio bought a new position in Sutro Biopharma in the 1st quarter worth $99,000. Marshall Wace LLP purchased a new stake in shares of Sutro Biopharma in the 2nd quarter worth about $166,000. Finally, Cerity Partners LLC lifted its position in shares of Sutro Biopharma by 169.9% in the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock worth $75,000 after purchasing an additional 66,372 shares during the period. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma News Roundup

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Two analyst upgrades with much higher price targets — HC Wainwright moved from Neutral to Buy and set a $28 target; Wells Fargo upgraded to Overweight with a $27 target — signaling renewed broker confidence and providing fresh buy-side impetus. Article Title
• Positive Sentiment: Pipeline progress: company reported dosing three cohorts in the Phase 1 trial of STRO-004 (TF ADC) and remains on track to report initial clinical data in mid‑2026 — a near‑term binary catalyst that can materially re-rate the stock if data are positive. Article Title
• Neutral Sentiment: Revenue beat: Sutro reported revenue of $11.65M versus analyst expectations of $9.26M, showing commercial or partnership receipts stronger than modeled — a positive data point, but offset by large GAAP losses. Press Release
• Neutral Sentiment: Short-interest data released for March shows zero reported short shares (and nonsensical NaN changes/days-to-cover numbers) — this appears to be a reporting/data issue and should not be interpreted as an actual clean short position. No reliable impact indicated.
• Negative Sentiment: Large EPS miss: Sutro reported a (-$5.39) EPS, missing consensus (-$4.66) by $0.73 and showing a very negative net margin and ROE — a reminder of high burn and continued operating losses that keep dilution risk and financing needs on the table. Press Release

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.